Covid-19 roundup: EMA starts re­view of SK’s vac­cine; Aus­tralian biotech switch­ing gears away from Covid re­search

An­oth­er Covid-19 vac­cine will en­ter the fray as the EMA kicks off its con­di­tion­al mar­ket­ing au­tho­riza­tion ap­pli­ca­tion for SK’s vac­cine, dubbed Sky­covion.

SK Chem­i­cals GmbH sub­mit­ted da­ta to the EMA on how well the vac­cine trig­gers the pro­duc­tion of an­ti­bod­ies against the orig­i­nal strain of SARS-CoV-2, along with da­ta on the safe­ty and qual­i­ty of the vac­cine.

“The eval­u­a­tion of Sky­covion is one of the on­go­ing eval­u­a­tions of da­ta on Covid-19 vac­cines. As the pan­dem­ic con­tin­ues to evolve, it is im­por­tant that the EU has a wide ar­ray of vac­cines and treat­ments to en­able the Mem­ber States to com­bat the pan­dem­ic ef­fec­tive­ly. EMA and its sci­en­tif­ic com­mit­tees are com­mit­ted to en­sur­ing a ro­bust re­view of all da­ta on COVID-19 vac­cines and med­i­cines,” the EMA said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.